TrialJournal for immunotherapy of cancer2020

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.

Kirsty Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.